In the news release, Arrayit Wins Landmark DNA Testing Patent in Israel, issued 04-Feb-2010 by Arrayit Corporation over PR Newswire, we are advised by the company that Patent Number 153848 in the first sentence of the second paragraph should link to the following website: http://www.ilpatsearch.justice.gov.il/UI/MainPage.aspx. The complete, corrected release follows:
Arrayit Wins Landmark DNA Testing Patent in Israel
New Technology Promises Economies of Scale in Healthcare
SUNNYVALE, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Arrayit Corporation (OTC Bulletin Board: ARYC), a life sciences and healthcare technology leader, announced today that the Company has received patent protection in the State of Israel for its proprietary Variation Identification Platform(TM) (VIP(TM)) DNA testing technology. The Israeli patent extends Arrayit's current patent portfolio, which includes VIP patents in the United States, Singapore, New Zealand, China, South Korea, and the European Union.
Israeli Patent Number 153848 empowers Arrayit to develop and commercialize economical diagnostic tests for important medical conditions including human diseases. The VIP approach uses microarrays, which are diagnostic devices that contain thousands of patient samples printed as microscopic spots on a glass substrate. One VIP microarray can test up to 80,000 patient samples simultaneously, using miniaturization, automation and massively parallel VIP devices to acquire the medical information. Improved testing speed, accuracy and healthcare cost reductions are among the benefits of testing many patients at once.
Arrayit Corporation CEO, Rene Schena, stated, "We are pleased to obtain patent protection for our VIP technology in Israel. This important achievement adds to our already expansive intellectual property portfolio and will empower us to aggressively pursue new growth opportunities for our VIP products and services in this important region."
About Arrayit Corporation
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. Arrayit now offers over 650 products to a customer base of more than 10,000 clinics and research facilities, and more than 5,000 laboratories worldwide, including almost every major university, pharmaceutical and biotech company, major agricultural and chemical companies, government agencies, national research foundations and many private sector enterprises. Please visit www.arrayit.com for more information.
Safe Harbor Statement
We have identified forward-looking statements by using words such as "expect," "believe," and "should." Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K/A for the fiscal year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March 31, 2009, Form 10-Q/A for the fiscal second quarter ended June 30, 2009 and Form 10-Q for the fiscal third quarter ended September 30, 2009.
FOR MORE INFORMATION, PLEASE CONTACT:
SOURCE Arrayit Corporation